Peptide inhibition of glomerular deposition of an anti-DNA antibody

Bruce Gaynor, Chaim Putterman, Philippe Valadon, Linda Spatz, Matthew D. Scharff, Betty Diamond

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Antibodies to double-stranded DNA are pathognomonic of systemic lupus erythematosus and deposit in the kidneys of lupus patients to cause glomerulonephritis. Recent data suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and be sequestered in the kidney by virtue of this cross-reactivity. If this is true, antigenic competition for pathogenic antibodies might prevent their deposition in kidneys and the ensuing tissue damage. To generate surrogate antigens that could be used for this purpose, we have used peptide display phage libraries to identify peptides that react with R4A, a pathogenic mouse monoclonal anti- DNA antibody that deposits in glomeruli. We have demonstrated that the peptides bind in or near the double-stranded DNA binding site. Furthermore, the peptides are bound preferentially by the R4A antibody as compared with two closely related antibodies derived from it, one of which deposits in renal tubules and one of which displays no renal pathogenicity. Administration of one of these peptides in a soluble form protects mice from renal deposition of the R4A anti-DNA antibody in vivo. This represents a new therapeutic approach in systemic lupus erythematosus that focuses on protecting target organs from antibody mediated injury.

Original languageEnglish (US)
Pages (from-to)1955-1960
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number5
DOIs
StatePublished - Mar 4 1997

Fingerprint

Antinuclear Antibodies
Kidney
Peptides
Antibodies
Systemic Lupus Erythematosus
Antigens
Peptide Library
DNA
Glomerulonephritis
Virulence
Binding Sites
Monoclonal Antibodies
Wounds and Injuries

Keywords

  • cross-reactivity
  • lupus nephritis
  • peptide library
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Peptide inhibition of glomerular deposition of an anti-DNA antibody. / Gaynor, Bruce; Putterman, Chaim; Valadon, Philippe; Spatz, Linda; Scharff, Matthew D.; Diamond, Betty.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 5, 04.03.1997, p. 1955-1960.

Research output: Contribution to journalArticle

@article{0df57e7b01e74f23bc07fb6111f3c881,
title = "Peptide inhibition of glomerular deposition of an anti-DNA antibody",
abstract = "Antibodies to double-stranded DNA are pathognomonic of systemic lupus erythematosus and deposit in the kidneys of lupus patients to cause glomerulonephritis. Recent data suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and be sequestered in the kidney by virtue of this cross-reactivity. If this is true, antigenic competition for pathogenic antibodies might prevent their deposition in kidneys and the ensuing tissue damage. To generate surrogate antigens that could be used for this purpose, we have used peptide display phage libraries to identify peptides that react with R4A, a pathogenic mouse monoclonal anti- DNA antibody that deposits in glomeruli. We have demonstrated that the peptides bind in or near the double-stranded DNA binding site. Furthermore, the peptides are bound preferentially by the R4A antibody as compared with two closely related antibodies derived from it, one of which deposits in renal tubules and one of which displays no renal pathogenicity. Administration of one of these peptides in a soluble form protects mice from renal deposition of the R4A anti-DNA antibody in vivo. This represents a new therapeutic approach in systemic lupus erythematosus that focuses on protecting target organs from antibody mediated injury.",
keywords = "cross-reactivity, lupus nephritis, peptide library, systemic lupus erythematosus",
author = "Bruce Gaynor and Chaim Putterman and Philippe Valadon and Linda Spatz and Scharff, {Matthew D.} and Betty Diamond",
year = "1997",
month = "3",
day = "4",
doi = "10.1073/pnas.94.5.1955",
language = "English (US)",
volume = "94",
pages = "1955--1960",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - Peptide inhibition of glomerular deposition of an anti-DNA antibody

AU - Gaynor, Bruce

AU - Putterman, Chaim

AU - Valadon, Philippe

AU - Spatz, Linda

AU - Scharff, Matthew D.

AU - Diamond, Betty

PY - 1997/3/4

Y1 - 1997/3/4

N2 - Antibodies to double-stranded DNA are pathognomonic of systemic lupus erythematosus and deposit in the kidneys of lupus patients to cause glomerulonephritis. Recent data suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and be sequestered in the kidney by virtue of this cross-reactivity. If this is true, antigenic competition for pathogenic antibodies might prevent their deposition in kidneys and the ensuing tissue damage. To generate surrogate antigens that could be used for this purpose, we have used peptide display phage libraries to identify peptides that react with R4A, a pathogenic mouse monoclonal anti- DNA antibody that deposits in glomeruli. We have demonstrated that the peptides bind in or near the double-stranded DNA binding site. Furthermore, the peptides are bound preferentially by the R4A antibody as compared with two closely related antibodies derived from it, one of which deposits in renal tubules and one of which displays no renal pathogenicity. Administration of one of these peptides in a soluble form protects mice from renal deposition of the R4A anti-DNA antibody in vivo. This represents a new therapeutic approach in systemic lupus erythematosus that focuses on protecting target organs from antibody mediated injury.

AB - Antibodies to double-stranded DNA are pathognomonic of systemic lupus erythematosus and deposit in the kidneys of lupus patients to cause glomerulonephritis. Recent data suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and be sequestered in the kidney by virtue of this cross-reactivity. If this is true, antigenic competition for pathogenic antibodies might prevent their deposition in kidneys and the ensuing tissue damage. To generate surrogate antigens that could be used for this purpose, we have used peptide display phage libraries to identify peptides that react with R4A, a pathogenic mouse monoclonal anti- DNA antibody that deposits in glomeruli. We have demonstrated that the peptides bind in or near the double-stranded DNA binding site. Furthermore, the peptides are bound preferentially by the R4A antibody as compared with two closely related antibodies derived from it, one of which deposits in renal tubules and one of which displays no renal pathogenicity. Administration of one of these peptides in a soluble form protects mice from renal deposition of the R4A anti-DNA antibody in vivo. This represents a new therapeutic approach in systemic lupus erythematosus that focuses on protecting target organs from antibody mediated injury.

KW - cross-reactivity

KW - lupus nephritis

KW - peptide library

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0031041542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031041542&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.5.1955

DO - 10.1073/pnas.94.5.1955

M3 - Article

VL - 94

SP - 1955

EP - 1960

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -